Valneva

News

Pfizer, Valneva Lyme vaccine starts review in Europe

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU.

News

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

Missing the primary endpoint in a phase 3 trial will not stop Pfizer from submitting Valneva-partnered Lyme disease vaccine for approval.

News

France probes side effects with Valneva's chikungunya jab

France's national public health agency has halted dosing of Valneva's chikungunya vaccine in older people while it investigates a safety signal.

News

Bavarian Nordic chikungunya vaccine gets FDA okay

There are now two vaccines to protect against chikungunya approved for use in the US, after Bavarian Nordic gets the green light for Vimkunya.

News

CHMP backs Bavarian Nordic's chikungunya jab

Bavarian Nordic is likely just weeks away from bringing the second chikungunya vaccine to the EU, and the first approved for use in adolescents.

News

Data builds behind Valneva, Pfizer's Lyme disease vaccine

New data for Valneva and Pfizer's experimental vaccine for Lyme disease – the furthest ahead in clinical testing – have bolstered the case for the shot as the results of a phase 3 programme

Pfizer, Valneva Lyme vaccine starts review in Europe

Pfizer, Valneva shrug off phase 3 Lyme disease vaccine miss

France probes side effects with Valneva's chikungunya jab

Bavarian Nordic chikungunya vaccine gets FDA okay

CHMP backs Bavarian Nordic's chikungunya jab

Data builds behind Valneva, Pfizer's Lyme disease vaccine

ESC26: Isomab safety evidence on blood vessel growth for CAD

Discover a new era of healthcare panel engagement: Grounded ...

Valneva

Editor's Picks